Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) issued its earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06, FiscalAI reports.
Larimar Therapeutics Price Performance
NASDAQ LRMR opened at $2.99 on Wednesday. Larimar Therapeutics has a 1 year low of $1.91 and a 1 year high of $6.42. The stock has a market capitalization of $310.60 million, a PE ratio of -1.83 and a beta of 0.73. The company’s 50 day simple moving average is $2.90 and its two-hundred day simple moving average is $3.75.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on LRMR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, October 15th. Wall Street Zen cut Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Wedbush dropped their price objective on Larimar Therapeutics from $11.00 to $9.00 and set an “outperform” rating on the stock in a report on Monday. Finally, Leerink Partners initiated coverage on Larimar Therapeutics in a report on Monday, September 14th. They set an “outperform” rating and a $13.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Larimar Therapeutics presently has a consensus rating of “Buy” and an average price target of $10.00.
Read Our Latest Research Report on Larimar Therapeutics
Insider Activity
In other news, CEO Carole Ben-Maimon purchased 18,050 shares of Larimar Therapeutics stock in a transaction dated Wednesday, November 11th. The stock was purchased at an average cost of $2.77 per share, for a total transaction of $49,998.50. Following the transaction, the chief executive officer directly owned 386,326 shares of the company’s stock, valued at approximately $1,070,123.02. This trade represents a 4.90% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Michael Celano purchased 18,460 shares of Larimar Therapeutics stock in a transaction dated Wednesday, November 11th. The shares were purchased at an average price of $2.71 per share, with a total value of $50,026.60. Following the completion of the transaction, the chief financial officer directly owned 234,245 shares in the company, valued at approximately $634,803.95. This represents a 8.55% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 140,810 shares of company stock valued at $381,955 in the last quarter. 4.00% of the stock is currently owned by company insiders.
About Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
Featured Stories
- Five stocks we like better than Larimar Therapeutics
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
